Zydus Cadila gets FDA OK for 2 generics

A new generic drug is now available to treat patients with ulcerative proctitis, which is a type of bowel disease. The Food and Drug Administration has cleared Zydus Cadila’s mesalamine suppositories for rectal use in a dosage strength of 1000 mg.

The product is an aminosalicylate anti-inflammatory drug that blocks the production of certain natural chemicals that may cause pain and swelling, according to the company.  

According to a report in the Hindu Business Line, the FDA also has approved Zydus Cadila’s generic fluocinonide cream, in a dosage strength of 0.1%.

Both generic drugs will be manufactured at the group’s topical manufacturing facility at Ahmedabad.